Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1184 articles with Regeneron Pharmaceuticals, Inc.
-
Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
7/1/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories.
-
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
6/29/2022
If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens.
-
Intellia Therapeutics and Regeneron Pharmaceuticals presented positive interim data from an ongoing Phase I trial of NTLA-2001 for transthyretin (ATTR) amyloidosis.
-
The life science industry is growing rapidly, and many companies have announced expansions and job creation. Still, others have been forced to cut costs and slash jobs. For that and more, continue reading.
-
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR)
6/24/2022
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts.
-
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
6/24/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
-
Regeneron has broken ground on a $1.8 billion expansion of its Tarrytown, NY facilities that will add at least 1,000 new full-time jobs.
-
According to recent BioSpace research, diversity and inclusion is an important factor when considering a new employment opportunity for 85% of life sciences community members.
-
The approval expands the rapidly growing number of indications for Dupixent, which is the first and only biologic medication with the FDA's nod to treat atopic dermatitis from infancy to adulthood.
-
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
6/7/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
-
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
6/7/2022
The U.S. Food and Drug Administration has approved Dupixent® for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
-
June is starting off with a number of important dates for the FDA, including an advisory committee meeting to discuss COVID-19 vaccines in children as young as six months.
-
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
6/2/2022
Regeneron will secure global rights to Libtayo from Sanofi in exchange for upfront payment of $900 million , plus royalties and potential future milestone payments.
-
Regeneron Pharmaceuticals announced intentions to acquire Sanofi’s stake in a drug they developed together, Libtayo (cemiplimab).
-
Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)
6/2/2022
Paris, June 2, 2022. Sanofi restructures its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Under the amended and restated license and collaboration agreement, Regeneron will obtain worldwide exclusive license rights to Libtayo.
-
Regeneron Completes Acquisition of Checkmate Pharmaceuticals
5/31/2022
Acquisition strengthens Regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment.
-
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
5/31/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® Medical to treat adults with prurigo nodularis, a chronic skin disease that causes extreme itch and inflammatory skin lesions.
-
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
5/31/2022
The U.S. Food and Drug Administration has accepted for priority review the supplemental Biologics License Application for Dupixent® to treat adults with prurigo nodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions.
-
Portland-based Children's Cancer Therapy Development Institute is discovering more targeted drugs for childhood cancers and driving them into clinical development with industry partner Artisan Biopharma.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.